Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Definition of "sefl police"...
I'll cut you in on my bribe if you don't rat me out...
Note - those options are worthless at the level LWLG is currently trading at.
Thinkabboudit...
MM's don't even mess with BONAR stocks.
But not the Big Boys...
LWLG - Yesterday's open vs today's:
06/25/24 09:46:32 3.05 3.04 3.06 3
06/25/24 09:46:32 3.05 3.04 3.06 100
06/25/24 09:46:23 3.05 3.04 3.06 100
06/25/24 09:46:16 3.04 3.04 3.06 2
06/25/24 09:45:34 3.04 3.04 3.06 100
06/25/24 09:45:01 3.04 3.04 3.06 5
06/25/24 09:45:01 3.04 3.04 3.06 100
06/25/24 09:43:50 3.04 3.04 3.06 4
06/25/24 09:43:39 3.04 3.04 3.06 57
06/25/24 09:43:18 3.04 3.04 3.06 4
06/25/24 09:43:18 3.04 3.04 3.06 6
06/25/24 09:41:37 3.04 3.04 3.06 100
06/25/24 09:41:34 3.05 3.04 3.06 396
06/25/24 09:41:22 3.03 3.03 3.05 100
06/25/24 09:41:13 3.034 3.03 3.05 3
06/25/24 09:41:11 3.034 3.03 3.05 1,000
06/25/24 09:39:09 3.05 3.02 3.05 100
06/25/24 09:38:41 3.02 3.02 3.05 100
06/25/24 09:38:20 3.02 3.02 3.05 59
06/25/24 09:36:39 3.02 3.02 3.06 1,000
06/25/24 09:34:40 3.06 3.02 3.08 100
06/25/24 09:34:07 3.02 3.02 3.07 100
06/25/24 09:32:38 3.045 3.02 3.07 53
06/25/24 09:32:38 3.045 3.02 3.07 100
06/25/24 09:30:45 3.04 3.04 3.09 1,497
06/25/24 09:30:04 3.06 3.04 3.08 1
06/25/24 09:30:01 3.06 3.05 3.09 1
06/24/24 09:45:28 3.1351 3.13 3.14 3
06/24/24 09:45:19 3.1351 3.13 3.14 57
06/24/24 09:45:13 3.1351 3.13 3.15 1,240
06/24/24 09:44:29 3.15 3.13 3.15 230
06/24/24 09:44:28 3.13 3.13 3.15 9,035
06/24/24 09:44:23 3.1601 3.16 3.18 100
06/24/24 09:44:23 3.1601 3.16 3.18 3,246
06/24/24 09:43:56 3.18 3.16 3.18 49
06/24/24 09:43:56 3.18 3.16 3.18 15
06/24/24 09:43:35 3.18 3.16 3.18 68
06/24/24 09:43:19 3.18 3.16 3.19 72
06/24/24 09:42:53 3.18 3.17 3.19 1
06/24/24 09:42:21 3.18 3.17 3.18 1,000
06/24/24 09:42:19 3.20 3.16 3.19 80
06/24/24 09:41:19 3.20 3.17 3.20 70
06/24/24 09:41:18 3.20 3.17 3.21 410
06/24/24 09:40:12 3.16 3.16 3.19 30
06/24/24 09:40:12 3.16 3.16 3.19 13
06/24/24 09:40:09 3.16 3.16 3.19 8
06/24/24 09:39:49 3.16 3.16 3.18 4
06/24/24 09:38:41 3.16 3.15 3.18 31
06/24/24 09:38:28 3.16 3.15 3.18 202
06/24/24 09:38:19 3.16 3.15 3.18 33
06/24/24 09:38:04 3.16 3.15 3.18 600
06/24/24 09:37:27 3.17 3.16 3.18 400
06/24/24 09:37:20 3.16 3.15 3.18 125
06/24/24 09:37:19 3.16 3.15 3.17 178
06/24/24 09:37:16 3.1613 3.16 3.18 5,000
06/24/24 09:37:06 3.17 3.16 3.18 100
06/24/24 09:36:19 3.176 3.16 3.17 22
06/24/24 09:36:10 3.176 3.16 3.18 850
06/24/24 09:35:42 3.16 3.15 3.20 4,015
06/24/24 09:35:17 3.14 3.14 3.16 5
06/24/24 09:35:00 3.14 3.13 3.16 544
06/24/24 09:34:39 3.135 3.13 3.14 1,000
06/24/24 09:34:36 3.13 3.13 3.14 200
06/24/24 09:34:28 3.12 3.11 3.14 1,200
06/24/24 09:34:13 3.1117 3.11 3.14 1,500
06/24/24 09:31:00 3.12 3.11 3.16 1
06/24/24 09:30:58 3.12 3.11 3.16 200
06/24/24 09:30:33 3.10 3.08 3.12 1,400
06/24/24 09:30:12 3.10 3.08 3.13 3,000
06/24/24 09:30:04 3.09 3.07 3.10 79
06/24/24 09:30:02 3.09 3.05 3.09 1
06/24/24 09:30:01 3.09 3.05 3.10 4
06/24/24 09:30:00 3.09 3.05 3.10 8,546
06/24/24 09:08:29 3.13 2.80 3.80 1
06/24/24 09:06:25 3.13 2.80 3.80 5
06/24/24 08:37:09 3.14 2.80 3.80 1
06/24/24 08:36:37 3.14 2.80 3.80 1
06/24/24 08:27:36 3.14 2.80 3.80 100
The first thing that pops into my mind is to maximize ip control.
Not prepared to argue it, but it seems plausible based on what I understand of this situation.
Repost - see replied to post:
This is essentially how the Anson family of funds (is Anson at the top of this family?) work SINT and its offerings.
Here is a trade that is almost guaranteed to make money, though it is also double super illegal.
These companies -- there were 13 of them, all pretty small -- raised money through what the SEC calls "confidentially marketed public offerings." A company would engage an investment bank, which would call up potential investors and ask if they wanted to buy shares in the company. The bank would do this before the company publicly announced the offering, and would "wall-cross" the potential investors, making them agree to keep the information about the offering secret until it was announced publicly.
So here's a predictable stock-market pattern and an easy way to exploit it: If a company calls you up to ask you to invest in its upcoming public offering, you should (1) say yes, (2) sell the company's stock short before the public announcement, and then (3) buy the stock back in the public offering, generally at a 10+ percent discount, a few days later.
This is of course not legal advice! It is a great trade, but it is also double super illegal, insofar as:
There is a specific SEC rule against short selling stock just before a public offering and then buying back the stock in the offering, 5 and
There is a general, and much more important, rule against trading on purloined material nonpublic information, and this is that.
trading in breach of that agreement, you are clearly violating not just the contract, but also insider trading laws, which make it illegal to trade "in breach of a fiduciary duty or other relationship of trust and confidence, while in possession of material, nonpublic information about the security."
But, you know, who will check?
Some of the funds would get wall-crossed, and then they'd tip each other and trade in the other funds to try to obscure what was going on:
When they were successful in obtaining such information, Fishoff shorted the issuer’s stock in advance of the offerings, directed trading by Chernin and Costantin in those instances when he did not place the trades on his own, and tipped Petrello, who then also shorted the stock through Brielle and Oceanview.
In many instances, the Fishoff-controlled entities for which Chernin and Costantin were fronting also participated in the offering, with the stock going to Featherwood’s account and often being used to cover the short sales.
By cheating on their wall-cross agreements and shorting the stock, these guys had the effect of driving down the stock price, which probably reduced the price in the offering. These companies probably got less money for their stock because their nonpublic information was (allegedly) used against them.
Though you could have a more cynical view of this sort of thing. A company needs to sell stock, but worries that announcing a public offering will drive down its stock price and not produce any takers. So it calls some investors up privately and tells them it's doing a deal. Those investors agree to invest in the deal, but before the deal is announced they lay off their risk by shorting the company's stock. Then the deal is announced and the investors buy shares from the company to (illegally) cover their shorts. The investors get their 10 percent, or whatever, discount to the market price as a commission; their real function is not to invest in the deal but to intermediate between the company (which can't sell stock without a publicly disclosed offering) and the unsuspecting public (which buys from the "investors" before the public disclosure). The wall-cross agreement creates deniability for the company. No one's stealing from the company; they're helping the company get a deal done that would otherwise be much harder to achieve. The victims are the public who buy from the insider traders at the inflated, pre-announcement price.
The 10000 can be wash traded back and forth freely between colluding computers. Tons of money is made so they can now walk the stock down even lower because risk has been reduced.
Repost, see replied to post:
Things just go SOOOO much more interesting with this revelation. It shows there has in fact been a conspiracy of funds, shorting and distorting Sint & Sintx since 2015. My next post will give some insight into how this family of funds might operate. This includes shorting before offerings exactly as ive said was occurring but it looks like the other funds do the shorting and then cover with the shares the fund that bought the offering received. Also seems to include wash trading back n forth just like Xenalives has posted in the past.
Plaintiff further asserts that many of the potential investors that it contacted on behalf of Defendant operate as a family of hedge funds, all managed by the same investment advisor.
List named the following:
• Anson Funds Management LP and its affiliates
• Ayrton Capital, Altos Opportunity Fund and their
affiliates
• Crede Capital Group, Acquitas Capital and its affiliates
• CVI Investment, Heights Management, SIG and their
affiliates
• Connective Capital and its affiliates
• Empery Asset Management and its affiliates
• Intracoastal Capital LP and its affiliates
• Hudson Bay Capital Management and its affiliates
• Ionic Venture LLC and its affiliates
• Lind Partners and its affiliates
• Li Capital Global Opportunities Master Fund and their
affiliates
• Sabby Management LLC and its affiliates
This Schedule 13G (this “Schedule 13G”) is being filed on behalf of Frigate Ventures LP (d/b/a Anson Group), a Texas limited partnership (“Frigate”), Admiralty Advisors LLC, a Texas limited liability company (“Admiralty”), Mr. Bruce R. Winson, the principal of Frigate and Admiralty, M5V Advisors Inc. (d/b/a Anson Group Canada), an Ontario, Canada corporation (“M5V”), Mr. Adam Spears, a director of M5V, and Mr. Moez Kassam, a director of M5V, relating to Common Stock, $.01 par value (the “Common Stock”), of Amedica Corporation, a Delaware corporation (the “Issuer”).
It appears that SiNtx is controlled financially by scammers that won't allow the tech into the market until they've milked every penny they can out of old drugs the shift will be sudden and violent.
Your point about accumulated deficit is significant, IMO.
Revenues will speak for themselves :)
You're right - it didn't last long....
Actually it looks like the usual wash trading between BONAR BUDDIES....
date, time,last, bid, ask, volume
06/24/24 14:54:16 0.18 0.18 0.19 1,500
06/24/24 14:53:45 0.185 0.18 0.19 5,000
06/24/24 14:53:04 0.184 0.18 0.188 10,000
06/24/24 14:52:16 0.1824 0.18 0.188 5,500
06/24/24 14:49:35 0.18 0.18 0.188 15,555
06/24/24 13:46:55 0.178 0.1655 0.188 269
06/24/24 13:22:26 0.19 0.1651 0.19 500
06/24/24 13:06:13 0.177 0.1651 0.1888 100
06/24/24 12:24:54 0.18 0.1651 0.19 500
06/24/24 12:15:36 0.1802 0.153 0.19 500
06/24/24 11:01:44 0.1702 0.1703 0.19 2,800
06/24/24 10:38:51 0.1831 0.1702 0.19 1,000
06/24/24 10:25:39 0.1801 0.1702 0.19 500
06/24/24 10:05:42 0.18 0.1702 0.19 6,000
This sucker is barely trading...
Looks like PAINT from the BONAR BUDDIES to me...
date time last, bid, ask, volume
06/24/24 11:01:44 0.1702 0.1703 0.19 2,800
06/24/24 10:38:51 0.1831 0.1702 0.19 1,000
06/24/24 10:25:39 0.1801 0.1702 0.19 500
06/24/24 10:05:42 0.18 0.1702 0.19 6,000
06/21/24 15:58:49 0.1788 0.1688 0.18 5,750
06/21/24 15:44:16 0.18 0.172 0.18 200
06/21/24 15:43:35 0.18 0.172 0.18 100
06/21/24 15:43:34 0.176 0.172 0.18 500
06/21/24 15:42:22 0.18 0.172 0.183 1,400
06/21/24 15:29:28 0.1776 0.172 0.18 200
06/21/24 15:17:01 0.1731 0.1701 0.18 1,666
06/21/24 14:50:19 0.1825 0.17 0.185 200
06/21/24 14:30:53 0.1763 0.17 0.1825 400
06/21/24 12:59:49 0.1788 0.17 0.1788 1,166
06/21/24 12:59:41 0.1744 0.17 0.1788 500
06/21/24 10:50:27 0.1792 0.1694 0.1825 2,000
06/21/24 10:49:45 0.1785 0.1693 0.1825 2,000
06/21/24 10:48:51 0.1792 0.1693 0.1825 2,000
06/21/24 09:39:08 0.1767 0.1679 0.1825 500
06/21/24 09:30:01 0.185 0.1676 0.1825 2,000
06/21/24 09:30:00 0.1675 0.1675 0.1825 582
WOW!!! A 10 billion dollar chip....
Situational awareness - a report on AI...
https://situational-awareness.ai/wp-content/uploads/2024/06/situationalawareness.pdf
See this thread for upcoming presentation info:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174643642
Still employed by IBM and connecting to BONAR ??????
Brian C. McGoff
Brian C. McGoff is a leader in the IBM World Wide Business Intelligence Group. McGoff has written and spoken widely on issues in data warehousing and business intelligence. He can be reached at bmcgoff@us.ibm.com.
JLPTNG posting 100% B.S. as revenge for the truth I post about a pump and dump penny run buy a scammer who's been playing that game for around 50 years.
Do your own DD - JLPTNG is a fool who plays penny stock cons. It seems he is intellectually incapable of understanding a stock like Lightwave, a solid tech stock with ground breaking I.P.
600 mg 3x per day is a conservative and biologically active dosage level.
Click on this profile and get this note:
About this profile
Sarah Shafer
JoinedJoined
September 2019September 2019
Contact informationContact information
Updated over 1 year agoUpdated over 1 year ago
Profile photoProfile photo
Updated less than 6 months agoUpdated less than 6 months ago
VerificationsVerifications
IdentityIdentity
Verified by CLEAR using government IDVerified by CLEAR using government ID
Less than 6 months agoLess than 6 months ago
Learn how members verify information
Verify for freeVerify for free
Show authenticity to boost trust.
This link and others point to probable promoters (co-conspirators) in the current BONAR con.
Note that IBM connections are mentioned. This is where BONAR got his start.
https://www.linkedin.com/in/brian-mcgoff-848411/
So bogus...
https://www.linkedin.com/in/brian-mcgoff-848411/
v
SO MUCH BONAR B.S.
Overview
Founded in 2004, Deposition Technology Limited (Deptec) is now a leading international company in precision manufacturing and services, specializing in PVD (Physical Vapor Deposition) and CVD (Chemical Vapor Deposition) processing and equipment.
Deptec excels in providing advanced remanufacturing capabilities and robust upgrades for businesses in the semiconductor, micro-electromechanical systems (MEMS), medical, and optoelectronics device industries. Ensuring that legacy systems continue to function by updating them with the latest technology and advanced features.
Deptec is committed to continuous innovation through R&D programs, aiming to build the next generation of precision equipment and upgrades. If you need assistance in sustaining or enhancing your processing capabilities, contact Deptec to explore how we can help.
Website
http://www.deptec.com
Phone
+441506901313Phone number is +441506901313
Industry
Semiconductor Manufacturing
Company size
2-10 employees
5 associated members LinkedIn members who’ve listed Deptec, a Dalrada Company as their current workplace on their profile.
Headquarters
Livingston, Scotland
Specialties
PVD and CVD
This so totally sucks - BONAR says DFCO acquired this P.O.S. :
https://twitter.com/bri35341840/status/1735461914958848230/photo/1
It continues to operate independently and if DFCO goes belly up, BRIAN BONAR and his son's widow continue to control this entity.
https://find-and-update.company-information.service.gov.uk/company/SC262730/officers
I did not have lung congestion - it was more like collapse of cellular and metabolic function...
From AI:
N-Acetylcysteine (NAC) can help restore cellular homeostasis in a number of ways:
Glutathione (GSH) levels
NAC is a precursor to GSH synthesis, and can help restore GSH levels that have been depleted. GSH is a key endogenous thiol antioxidant that can be depleted during oxidative stress. Restoring GSH levels can help prevent apoptosis caused by GSH depletion.
Redox homeostasis
NAC can help restore redox homeostasis that has been disrupted by viral infections, such as SARS-CoV-2, which overproduces reactive oxygen species (ROS).
Protein quality control
Loss of NAC can activate the ER stress response, which can lead to cell death. NAC plays a crucial role in protein quality control and maintaining cellular homeostasis.
MDPI
Mitochondrial Glutathione in Cellular Redox Homeostasis and ...
NAC supplementation may restore cellular GSH levels and prevent apoptosis caused by GSH de...
Nature
Naca protects the larval fat body from cell death by ... - Nature
Sep 1, 2023 — In several species and cell lines, the loss of NAC activates the ER stress resp...
NCBI
N-Acetyl Cysteine Restores the Diminished Activity of ... - NCBI
Apr 14, 2023 — SARS-CoV-2 infects type II pneumocytes and disrupts redox homeostasis by overp...
IOVS
N-Acetylcysteine Amide Protects Against Oxidative Stress ...
... NAC.73–76 One of the key endogenous thiol antioxidants is GSH, which is depleted durin...
NAC has also been used to treat other conditions, including:
Respiratory diseases
NAC supplementation can help replenish GSH levels in patients with respiratory diseases, and may also help with pulmonary recovery.
COPD
NAC has been shown to attenuate lung damage, emphysema, and alveolar septal cell apoptosis in rats with cigarette smoke-induced COPD.
NAC has antioxidant and anti-inflammatory properties, and has been used as an over-the-counter nutritional supplement in the United States, Canada, and Australia for decades. However, continuous NAC treatment beyond the injury phase can delay regeneration by impairing mitochondrial biogenesis.
This is for informational purposes only. For medical advice or diagnosis, consult a professional. Generative AI is experimental.
N-acetylcysteine (NAC) comes from the amino acid L-cysteine and has been a Food and Drug Administration (FDA) approved drug since 1963. It is recognized as the standard treatment for acetaminophen overdose and has been used as a mucolytic drug since the 1960s [1]. NAC has also been used as a supplement for decades and, as such, can be found as an over-the-counter nutritional supplement in countries such as the United States, Canada, and Australia [1]. Therefore, NAC falls into a grey zone with other compounds such as cannabidiol (CBD), but as of August 2022, the FDA has backed away from its hard stance on classifying NAC as a drug and is allowing its sale as a dietary supplement [2]. NAC’s antioxidant and anti-inflammatory properties make it a promising therapeutic agent for conditions in which oxidative stress is involved [1]. Examples of these disorders include diabetes, obesity, cancer, neurological disorders, hypertension, pulmonary, inflammatory bowel, cardiovascular, autoimmune, and infectious diseases in humans, as well as domesticated animal weaning disorders, respiratory disease, diarrhea, endometritis, and mastitis [3,4,5,6,7,8,9,10].
While there has been an increasing interest in the use of NAC for a wide range of pathological conditions over the past few decades, various human clinical studies have reported conflicting results, and many other studies were performed in vitro. Therefore, more clinical studies are required to address these conflicting results and to support the purported therapeutic roles of NAC in treating different pathological conditions.
Various animal studies involving the use of NAC have also been performed, especially with its use in treating intestinal inflammation and related disorders that can be caused by anti-nutritional factors (e.g., ß-conglycinin, a vicilin storage protein of soybeans), the process of weaning, and consumption of mycotoxins [10,11,12]. Many studies have shown the protective effects of NAC for neonatal animals immune challenged with bacterial lipopolysaccharide (LPS) endotoxin, particularly studies involving piglets [13,14]. NAC administration has consistently been shown to increase daily body weight gain and alleviate LPS-mediated growth depression. Furthermore, the porcine model of ulcerative colitis (UC) can be used to support NAC usage for humans. For example, in a study conducted by Wang et al. (2013), the piglet model of UC demonstrated that administration of NAC was able to reduce colon histopathology score and ameliorate UC histological abnormalities [15].
Despite the numerous NAC studies and its increasing popularity, the mechanisms of action (MOA) by which NAC exerts its antioxidant and cytoprotective properties remain unclear [1,16]. It is often assumed that the effects conferred by NAC are due to it acting as a scavenger of reactive oxygen species (ROS), a precursor for glutathione (GSH) biosynthesis, and a disulfide reductant [16,17]. However, these three major narratives can only explain the effects of NAC under specific circumstances [16,17]. Recently, an alternative MOA was proposed that may explain the effects attributed to NAC: the conversion of NAC into hydrogen sulfide and sulfane sulfur species, which are known to possess antioxidant and cytoprotectant properties [16,17]. Thus, the purpose of this review is to provide an overview of the therapeutic uses of NAC in both humans and domesticated species, with a particular focus on weaning disorders, as well as an overview of its MOA.
In the case of additional biological warfare against the human race:
(yes, that is what I believe COVID was and expect that there will be more attacks of that nature)
From AI:
N-Acetylcysteine (NAC) can help restore cellular homeostasis in a number of ways:
Glutathione (GSH) levels
NAC is a precursor to GSH synthesis, and can help restore GSH levels that have been depleted. GSH is a key endogenous thiol antioxidant that can be depleted during oxidative stress. Restoring GSH levels can help prevent apoptosis caused by GSH depletion.
Redox homeostasis
NAC can help restore redox homeostasis that has been disrupted by viral infections, such as SARS-CoV-2, which overproduces reactive oxygen species (ROS).
Protein quality control
Loss of NAC can activate the ER stress response, which can lead to cell death. NAC plays a crucial role in protein quality control and maintaining cellular homeostasis.
MDPI
Mitochondrial Glutathione in Cellular Redox Homeostasis and ...
NAC supplementation may restore cellular GSH levels and prevent apoptosis caused by GSH de...
Nature
Naca protects the larval fat body from cell death by ... - Nature
Sep 1, 2023 — In several species and cell lines, the loss of NAC activates the ER stress resp...
NCBI
N-Acetyl Cysteine Restores the Diminished Activity of ... - NCBI
Apr 14, 2023 — SARS-CoV-2 infects type II pneumocytes and disrupts redox homeostasis by overp...
IOVS
N-Acetylcysteine Amide Protects Against Oxidative Stress ...
... NAC.73–76 One of the key endogenous thiol antioxidants is GSH, which is depleted durin...
NAC has also been used to treat other conditions, including:
Respiratory diseases
NAC supplementation can help replenish GSH levels in patients with respiratory diseases, and may also help with pulmonary recovery.
COPD
NAC has been shown to attenuate lung damage, emphysema, and alveolar septal cell apoptosis in rats with cigarette smoke-induced COPD.
NAC has antioxidant and anti-inflammatory properties, and has been used as an over-the-counter nutritional supplement in the United States, Canada, and Australia for decades. However, continuous NAC treatment beyond the injury phase can delay regeneration by impairing mitochondrial biogenesis.
This is for informational purposes only. For medical advice or diagnosis, consult a professional. Generative AI is experimental.
N-acetylcysteine (NAC) comes from the amino acid L-cysteine and has been a Food and Drug Administration (FDA) approved drug since 1963. It is recognized as the standard treatment for acetaminophen overdose and has been used as a mucolytic drug since the 1960s [1]. NAC has also been used as a supplement for decades and, as such, can be found as an over-the-counter nutritional supplement in countries such as the United States, Canada, and Australia [1]. Therefore, NAC falls into a grey zone with other compounds such as cannabidiol (CBD), but as of August 2022, the FDA has backed away from its hard stance on classifying NAC as a drug and is allowing its sale as a dietary supplement [2]. NAC’s antioxidant and anti-inflammatory properties make it a promising therapeutic agent for conditions in which oxidative stress is involved [1]. Examples of these disorders include diabetes, obesity, cancer, neurological disorders, hypertension, pulmonary, inflammatory bowel, cardiovascular, autoimmune, and infectious diseases in humans, as well as domesticated animal weaning disorders, respiratory disease, diarrhea, endometritis, and mastitis [3,4,5,6,7,8,9,10].
While there has been an increasing interest in the use of NAC for a wide range of pathological conditions over the past few decades, various human clinical studies have reported conflicting results, and many other studies were performed in vitro. Therefore, more clinical studies are required to address these conflicting results and to support the purported therapeutic roles of NAC in treating different pathological conditions.
Various animal studies involving the use of NAC have also been performed, especially with its use in treating intestinal inflammation and related disorders that can be caused by anti-nutritional factors (e.g., ß-conglycinin, a vicilin storage protein of soybeans), the process of weaning, and consumption of mycotoxins [10,11,12]. Many studies have shown the protective effects of NAC for neonatal animals immune challenged with bacterial lipopolysaccharide (LPS) endotoxin, particularly studies involving piglets [13,14]. NAC administration has consistently been shown to increase daily body weight gain and alleviate LPS-mediated growth depression. Furthermore, the porcine model of ulcerative colitis (UC) can be used to support NAC usage for humans. For example, in a study conducted by Wang et al. (2013), the piglet model of UC demonstrated that administration of NAC was able to reduce colon histopathology score and ameliorate UC histological abnormalities [15].
Despite the numerous NAC studies and its increasing popularity, the mechanisms of action (MOA) by which NAC exerts its antioxidant and cytoprotective properties remain unclear [1,16]. It is often assumed that the effects conferred by NAC are due to it acting as a scavenger of reactive oxygen species (ROS), a precursor for glutathione (GSH) biosynthesis, and a disulfide reductant [16,17]. However, these three major narratives can only explain the effects of NAC under specific circumstances [16,17]. Recently, an alternative MOA was proposed that may explain the effects attributed to NAC: the conversion of NAC into hydrogen sulfide and sulfane sulfur species, which are known to possess antioxidant and cytoprotectant properties [16,17]. Thus, the purpose of this review is to provide an overview of the therapeutic uses of NAC in both humans and domesticated species, with a particular focus on weaning disorders, as well as an overview of its MOA.
That post is absolute horse pockey.
No link.
The timing you cite coordinates with a theory I have....
My first "significant other" was a spook. We lived together for years and tried to get back together a couple of times.
He died in 2019, and I believe it was COVID - not coincidence because late in 2019 I got COVID before the Drs. knew what it was.
I am only here because I was already taking NAC regularly and I realized how much it helped me so I took more.
I sincerely believe that COVID was a man made plague that was deliberately seeded in the population.
"What was achieved? "
We the People were disenfranchised, dispossessed, and in many cases made destitute.
This has been the plan for decades it seems...
So private deep pockets will be able to swarm in and scoop it up....
Got it......
Start reading here to understand how legitimate companies are being undermined by the current capitalist cabal:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174589960
Nonsensical statement:
I don't follow SAVA closely, but the market believes in their trials. They are running longer, bigger, better designed trials, unlike what the clown did—running smaller, lousy designed trials in obscure locations in Australia with made-up endpoints, and soon timeline. Ultimately, trial data, the FDA, and the market will decide the company's value. Right now, this POS is at $300 million despite the so-called successful Phase 2b (3) trial, while SAVA is at $1 billion with 2 Phase 3 in progress.
The motive... simple...
Fascist control of the world.
Coming soon to the U.S. if WE THE PEOPLE don't stand up to creeping fascism in our government...
https://www.visiontimes.com/2023/03/01/wef-partners-mayors-intervene-food-clothing-flights.html
Marwan Sabbagh, MD, is a behavioral neurologist in the Alzheimer’s and Memory Disorders Program at Barrow Neurological Institute. He is also a professor and the Vice Chair of Research in the Institute’s Department of Neurology. He is board certified in neurology by the American Board of Psychiatry and Neurology.
Dr. Sabbagh’s expertise includes the diagnosis and treatment of Alzheimer’s disease and other memory disorders. He is a fellow of the American Academy of Neurology.
Dr. Sabbagh earned his medical degree from the University of Arizona College of Medicine in Tucson and his undergraduate degree from the University of California—Berkeley. He completed his neurology residency at Baylor College of Medicine in Houston, Texas, and a geriatric neurology and dementia fellowship at the University of California San Diego School of Medicine.
Dr. Sabbagh is a leading investigator of many prominent national Alzheimer’s prevention and treatment clinical trials. He serves on the editorial boards of the Journal of Alzheimer’s Disease and Alzheimer’s and Dementia: Translational Research & Clinical Interventions. He is the editor-in-chief of Neurology and Therapy. Dr. Sabbagh is a prolific author who has written and edited books on Alzheimer’s disease and has contributed to hundreds of medical and scientific articles.
BONAR B.S. on linkedin...
Dalrada Financial Corporation™Dalrada Financial Corporation™
What makes Dalrada different?
We're recognized globally for our heat pumps, dedicated to keeping communities safe with healthcare services, and partnering with governments to drive lasting change. We make impactful solutions for years to come.
$DFCO #weightloss #greenpower
[
partnering with governments to drive lasting change. We make impactful solutions for years to come.
$DFCO #weightloss #greenpower/quote]
The above is 100% unsupported B.S.
Food for thought..
(This hero and prophet is now deceased)
Dr Zelenko’s Deathbed Message:
— Grant Taylor (@grantltaylor) June 30, 2022
Resist The WHO’s Fear Campaigns, Denounce The False gods Of Technology & Science, Turn Back To Our True Creator
Rest in peace pic.twitter.com/y8zMnEpZTP
Interesting article that shows the tension and complexity of dealing going on within the chip industry right now. The fact that Lebby is mum about the specifics of Lightwave's involvement is no surprise.
AI titans Microsoft and Nvidia reportedly had a standoff over use of Microsoft's B200 AI GPUs in its own server rooms https://t.co/Vj1W7wkjE2 pic.twitter.com/ZfZthfyGxk
— Tom's Hardware (@tomshardware) June 21, 2024
LOL!!!! I had to read this line several times, wondering what yetis had to do with AVXL....
but what we havent seen yetis